Capricor Therapeutics (CAPR) Other Non-Current Liabilities (2013 - 2014)
Capricor Therapeutics (CAPR) posted quarterly Other Non-Current Liabilities of $11.3 million for Q1 2014, up 182.02% quarter-over-quarter from $4.0 million in Q4 2013.
Powered by 
Analysis
Capricor Therapeutics (CAPR) Other Non-Current Liabilities (2013 - 2014) Analysis & Trends
Capricor Therapeutics' Other Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $11.3 million for Q1 2014.
- In Q1 2014, Other Non-Current Liabilities changed N/A year-over-year to $11.3 million; the TTM figure through Mar 2014 stood at $11.3 million (changed N/A YoY), while the FY2013 annual figure was $4.0 million, changed N/A from the prior year.
- Other Non-Current Liabilities for Q1 2014 stood at $11.3 million, up from $4.0 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $11.3 million in Q1 2014, with the low at $190863.0 in Q2 2012.
- The 3-year median for Other Non-Current Liabilities is $4.0 million (2013), against an average of $5.2 million.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Capricor Therapeutics | 543.30 Mn | 543.30 Mn | - |